Results 31 to 40 of about 6,848 (153)

Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals

Neurology and Therapy
Cladribine tablets have been granted marketing authorization in Europe and approved by the Food and Drug Administration (FDA) in the USA to treat relapsing forms of multiple sclerosis (MS).
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, Donna Nahal, Celia Oreja-Guevara, Saúl Reyes, Helen Gray, Hashem Salloukh, Gavin Giovannoni   +8 more
doaj   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Antibacterial mechanism and in vivo efficacy of cladribine against carbapenem-resistant Klebsiella pneumoniae

BMC Microbiology
Background The proliferation and dissemination of carbapenem-resistant Klebsiella pneumoniae (CRKP) constitutes a critical public health concern, underscoring the urgent need for novel antimicrobial agents.
Kai-Di Liu, Fan-Yue Wang, Jun-Qi Liu, Wei-Hua Hao, Li-Li Guo, Yong-Da Zhao, Xiao-Ping Liao, Min-Ge Wang   +7 more
doaj   +1 more source

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study

Frontiers in Immunology, 2021
BackgroundMultiple sclerosis (MS) is an incurable autoimmune disease mediated by a heterogeneous T cell population (CD3+CD161+CXCR3−CCR6+IFNγ−IL17+, CD3+CXCR3+CCR6+IFNγ+IL17+, and CD3+CXCR3+IFNγ+IL17− phenotypes) that infiltrates the central nervous ...
Minodora Dobreanu, Minodora Dobreanu, Minodora Dobreanu, Doina Ramona Manu, Ion Bogdan Mănescu, Ion Bogdan Mănescu, Manuela Rozalia Gabor, Adina Huţanu, Adina Huţanu, Laura Bărcuţean, Laura Bărcuţean, Rodica Bălaşa, Rodica Bălaşa   +12 more
doaj   +1 more source

Plasma Exosome Metabolomics Reveal Stage‐Specific Alterations in Elderly Women With Premetabolic and Metabolic Syndrome

Chronic Diseases and Translational Medicine, EarlyView.
Shared differential metabolites identified across the three sample groups. (A) Venn diagram of differential metabolites between the two comparison groups; Based on the detected levels of these overlapping differential metabolites, (B) d‐Arabitol, (C) Triclosan, (D) Iloprost, (E) Tetracosanoic acid, and (F) Omeprazole sulfone. Box plots were constructed
Mengtao Qian, Dan Nie, Qianyi Gao, Xingbo Mo, Huan Zhang   +4 more
wiley   +1 more source

Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry

Journal of Central Nervous System Disease
Background Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). Objectives Provide experience with cladribine therapy in a real-world setting. Methods This is a
Pavel Potuznik, Jiri Drahota, Dana Horakova, Marek Peterka, Aneta Mazouchova, David Matyas, Zbysek Pavelek, Marta Vachova, Eva Recmanova, Ivana Stetkarova, Jana Libertinova, Jan Mares, Pavel Stourac, Marketa Grunermelova, Alena Martinkova, Jana Adamkova, Pavel Hradilek, Radek Ampapa, Michal Dufek, Eva Kubala Havrdova, Dominika Stastna   +20 more
doaj   +1 more source

Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice

Неврология, нейропсихиатрия, психосоматика, 2020
Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple sclerosis (HAMS). After discussing the characteristics of action of the drug in clinical trials, the authors give their own experience of its use in the ...
S. V. Petrov, O. V. Boyko, A. N. Boyko
doaj   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, EarlyView.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source